Immatics Biotechnologies GmbH Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125

12:07 EST 1 Mar 2017 | BioPortfolio Reports

Immatics Biotechnologies GmbH Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This uptotheminute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.


Business description A detailed description of the company's operations and business divisions.
Corporate strategy GlobalData's summarization of the company's business strategy.
SWOT analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
Key manufacturing facilities A list of key manufacturing facilities of the company.


Immatics Biotechnologies GmbH Immatics is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, nonsmallcell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA300/301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of its drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH Key Recent Developments

Jan 08, 2016: Immatics Appoints Katina Dorton as Chief Financial Officer

Reasons to Buy

Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Original Article: Immatics Biotechnologies GmbH Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125


More From BioPortfolio on "Immatics Biotechnologies GmbH Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125"

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...